Coast IRB Heeds Call of Congress and Pledges Comprehensive Reforms
WASHINGTON, March 30 /PRNewswire/-Following yesterday's hearing of the House Subcommittee on Oversight and Investigations, Coast IRB CEO Dan Dueber announced that his company would institute immediate and sweeping reforms. "We share Congress's objective of ensuring maximum protection for human subjects in clinical trials," said Dueber. "We are instituting comprehensive reforms to prevent recurrence of the vulnerabilities the Subcommittee brought to light," he said. "Our number one priority is the protection of human subjects."
Today, Coast is sending a written post-hearing statement to the Subcommittee for inclusion in the record. That statement lists twelve specific reforms from background checks on every sponsor of a clinical trial to the hiring of an expert consultant to revamp Coast's IRB reviews. In addition, Coast is replacing the current chair of its IRB with a new chair and explains that the reform process will be continuing in nature even after the twelve specific reforms are instituted.
The reforms Coast now institutes may one day be required by law for all IRBs if Congress enacts legislation based on the Subcommittee's deliberations. "For Coast, this process of reform is not going to end," said Dueber. "We mean for it to be continuous, making reexamination and improvement a dynamic, not a static condition," he said. "Coast intends to exceed the requirements of the law, not just meet them."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
